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Abstract
Circulating tumour cells (CTCs) are important indicators
of metastatic cancer and may provide critical information
for individualized treatment. As CTCs are usually very
rare, the techniques to obtain information from very small
numbers of cells are crucial. Here, we propose a method to
perform a single cell quantitative reverse transcription
polymerase chain reaction (qPCR) analysis of rare tumour
cells. We utilized a microfluidic immunomagnetic assay to
separate cancer cells from blood. A combination of detailed
immunofluorescence and laser microdissection enabled
the precise selection of individual cells. Cancer cells that
were spiked into blood were successfully separated and
picked up for a single cell PCR analysis. The breast cancer
cell lines MCF7, SKBR3 and MDAMB231 were tested with
10 different genes. The result of the single cell analysis
matched the results from a few thousand cells. Some
markers (e.g., ER, HER2) that are commonly used for cancer
identification showed relatively large deviations in expres‐
sion levels. However, others (e.g., GRB7) showed devia‐
tions that are small enough to supplement single cell
disease profiling.
Keywords CTC, single cell PCR, breast cancer, immuno‐
magnetic assay, lab on a chip, laser microdissection
1. Introduction
Circulating tumour cells are cells that have detached from
a primary tumour and circulate in the blood stream[1, 2].
The detection and analysis of CTCs has been an object of
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interest because simple blood testing may indicate disease
activity, provide evidence of progressive disease and
diagnose cancer earlier. Several approaches, including the
commercially available CellSearch™ method [3, 4], have
been proposed and shown some success for the enumera‐
tion of CTCs in blood. However, techniques that allow for
a detailed genomic and immunofluorescence analysis of
separated cancer cells rather than a simple enumeration are
needed to exploit the potentially abundant information that
we may obtain from the CTC.
The polymerase chain reaction (PCR) is among the most
widely utilized techniques for the genomic analysis of
tumours [5]. A PCR analysis of CTCs is advantageous
because it may provide genomic information of tumours
that would otherwise be obtained from an invasive tumour
biopsy. An analysis of cancer cells from blood is challeng‐
ing because of the low cancer cell-blood cell ratio, which
could be as low as 1 to 107. It is also challenging because, in
many cases, the number of cancer cells found in 5-10 mL of
a patient’s blood is less than five. Approaches to carrying
out a PCR analysis for CTCs have been reported and some
allow for a single cell analysis [6-11]. However, reliable
techniques to study genomic information of individual
CTCs, which are also characterized by detailed immuno‐
fluorescence, are still to be studied. Conventional tools for
fluorescence-activated cell sorting [12-14] (FACS), such as
the BD FACSAria™, rely on cell fluorescence intensities but
are more suitable for sorting or enriching larger numbers
of target cells. In a CTC study, a detailed microscopic
observation of cell morphology, along with an immuno‐
fluorescence observation, is crucial to correctly identify the
very rare cancer cells. For a single cell PCR analysis, sample
purity is also a critical parameter. In order to discuss the
characteristics of the individual cancer cells that are of
interest, other blood cells should be eliminated from the
sample. A separation technique that is based on a detailed
immunofluorescence observation is needed for a single cell
PCR analysis of CTCs.
In this paper, we propose a method for a single cell PCR
analysis that is based on the microfluidic immunomagnetic
separation of cancer cells. A combination of a microscopic
fluorescence observation and the laser microdissection
technique [15] allows for the accurate separation of cancer
cells for the following single cell PCR analysis. In addition,
the collected cancer cells are fixed on standard microscope
glass slides and many existing microscopic observation
techniques can be used before carrying out a single cell PCR
analysis.
2. Results
2.1 Microchip-based Immunomagnetic Separation
Blood samples were drawn from a healthy donor using
CellSave™ tubes (Janssen Diagnostics, LLC, NJ). The
samples were then added with control breast cancer cell
lines. As model breast cancer cell lines for ER/PR positive,
HER2 positive and triple negative breast cancers, we used
MCF7, SKBR3 and MDAMB231 cell lines [16], respectively.
The cultured cells were harvested, centrifuged and resus‐
pended in buffer solution. The cells were then counted with
a haemocytometer and diluted in phosphate buffered
saline (PBS) to prepare a solution with a known concentra‐
tion of suspended cells. The number of cancer cells that
were added in 2.5 mL of the samples ranged from 5-1000.
Before microfluidic screening, the blood plasma was
replaced with a buffer and the red blood cells (RBCs) were
lysed and washed in order to reduce potential contami‐
nants for the single cell PCR. We centrifuged 2.5 mL aliquot
of blood and replaced the plasma with a buffer solution
(Veridex, LLC, NJ) to obtain a total of 3.5 mL of blood
solution. This was then added with a 1X lysis buffer
(BioLegend, CA). After 10 minutes of incubation, the
mixture was centrifuged for 5 minutes at 300 g (relative
centrifugal force). The supernatant was then aspirated and
the cell pellet was resuspended in a buffer solution (Veri‐
dex, LLC, NJ).
The details of our microchip-based separation method have
been reported elsewhere [17]. The blood samples were
added with a suspension of Fe3O4 magnetic nanoparticles
(size: 100-200 nm), functionalized with anti-epithelial cell
adhesion molecules (anti-EpCAM). The microchip-based
screening process started after 10 minutes of incubation.
Figure 1 shows diagrams of the experimental setup.The
cancer cells that were bound to the particles were collected
onto glass slides by permanent magnets as the blood
flowed through the microchip. On top of the glass sub‐
strates was a 3-µm-thick polyethylene naphthalate (PEN)
film. We used PEN film coated glass slides (Membrane
Slide 1.0 PEN), which were supplied by Carl Zeiss Ltd. The
surface of the PEN film was treated with a 0.01% (w/v)
solution of poly-L-lysine (Sigma). After blood screening, a
buffer solution was introduced to flush the unwanted
white blood cells (WBCs). The capture rate of the micro‐
fluidic system was defined as the number of cancer cells
that were found on the slide, divided by the number of cells
that were added to the blood sample. Details of the capture
efficiency that were tested with the spiked samples and
patient samples have been reported elsewhere [17-19]. For
the spiked experiments with SKBR3 and MCF7 cells, the
capture rates were consistently better than 90%. From the
patient samples, the number of cancer cells that were
typically found was 1-10. We have also seen previous cases
with more than 1000 cells in 2.5mL of blood [18].
Figure 1. The experimental setup of the microfluidic immunomagnetic
assay. The cancer cells labelled with EPCAM functionalized the magnetic
nanoparticles, which were attracted onto a PEN film-coated glass slide.
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2.2 Immunofluorescence-assisted Cell Identification and
Separation
The cells that were captured on the slide were fixed using
acetone and fluorescently stained with anti-cytokeratin
(mouse anti-cytokeratin, pan-FITC, Sigma-Aldrich, St.
Louis, MO) and anti-CD45 (AlexaFluor 594, Invitrogen,
Carlsbad, CA, bound to mouse anti-human clone 9.1) for
the positive and negative tests, respectively. The entire
slide was scanned manually by a trained observer and the
cancer cells were identified based on the fluorescence
intensity, size and morphology of the stained cells. Figure
2 shows example images of the cancer cells (the cells with
green fluorescence), which were captured on PEN film-
coated glass slides. Non-specifically captured WBCs (the
cells with red fluorescence) were also found with a certain
frequency, as shown in the images. The WBCs were
removed from the sample in the next step. We should note
that sample staining might degrade the quality of RNA, as
reported in literature [20, 21]. However, immunostaining
in laser microdissection-based RNA analyses is still
commonly used and has shown success [22, 23]. In the case
of a rare tumour cell analysis, the use of immunostaining
seems an acceptable compromise to identify the tumour
cells of interest from the majority of the white blood cells.
Figure 2. The captured breast cancer cells of (a) SKBR3 and (b) MCF7 stained
with FITC (green). Non-specifically captured WBCs stained with AlexaFluor
594 (red) are also found in the images. Separate photographs that were taken
with green and red filters are shown as overlay images.
Once a cancer cell was located, an area of about 500 µm ×
500 µm of the film containing the cell was cut by a focused
laser beam (see Figure 3(a)). We used a Zeiss PALM
MicroBeam Laser Microdissection. In this step, the contam‐
inating WBCs were identified with the CD45 fluorescent
marker through immunofluorescence. The areas contain‐
ing them were selectively cut out using a Laser Microdis‐
section. The number of WBCs in the 500 µm × 500 µm was
typically 3~5 or less. With the resolution of the laser tool (~a
few micrometres), most of the WBCs could be avoided or
safely removed from the cut portion, eliminating possible
contamination from the WBCs that non-specifically
remained on the slides after the microfluidic separation.
Figure 3(b) shows an example of a cut film, which contained
a MCF7 cancer cell. The top left corner of the cut rectangle
was trimmed to indicate the film’s orientation (upside
versus downside). In this example, one WBC was found
close to the cancer cell and was removed by laser cutting.
This left a void in the cut film. The film was manually
picked up by a needle under a microscopic observation and
placed onto the adhesive part of a specially designed PCR
tube (Zeiss AdhesiveCap tube). The size of the cut film (500
µm × 500 µm) was chosen for an experienced operator to
comfortably handle the film. After the film was placed, we
conducted a microscopic observation to verify the success‐
ful transfer of the cancer cells. We ensured that all of the
cancer cells were still visible and that the side of the cut film
containing the cancer cells was upside (i.e., the film’s
trimmed corner was in the top left) in order to directly
expose the cells to the reagents. The SEM of the cells
transferred in a tube is shown in Figure 7 in the Methods
section.
It took a few minutes for each film to be cut and transferred.
According to our experience with patient samples [18], the
number of CTCs that are found from 7.5mL of blood is
mostly between 1 and 5, and very rarely more than 50. In
addition, multiple cells are often found in clusters and can
be picked up in a single film. In most cases, all of the
identified cancer cells were picked up with reasonable
effort. With rare cases of more than 1000 cells, we could
randomly pick up ~50 cells to conduct the PCR analysis.
Figure 3. (a) Immunofluorescence-assisted selection of the single cancer cells
via a laser microdissection. A portion of the PEN film containing a single
cancer cell was cut into a small piece of about ~500 µm. (b) Fluorescence
image of a cut film. A white blood cell was removed by laser cutting (see the
small square-shaped void in the picture). The film was manually picked up
by a needle under a microscopic observation and placed onto the cap of a
PCR tube. The side of the cut film containing the cancer cells should have
been upside.
2.3 RNA Extraction and Reverse Transcription
We used a single cell RNA extraction kit (RNAGEM tissue,
ZyGEM Corp. Ltd) to extract mRNA from the sample. To
obtain cDNA through reverse transcription, qScriptcDNA‐
SuperMix (Quanta Biosciences) was used. The cDNA
sample was then added with a mixture of primers for target
DNA sequences and preamplified by 20-23 cycles before
being analysed in the microfluidic qPCR system (BioMark
HD System[24], Fluidigm Corporation and StepOne Plus,
Applied Biosystems).
We used primers for the gene sequences of UBB (referen‐
ces), ESR1 (for luminal or ER/PR+ cancer cells), HER2 and
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GRB7 (for HER2+ cancer cells), EPCAM, KRT7, KRT8,
KRT18, and KRT19, all of which have been commonly
discussed for the purpose of breast cancer diagnosis [7, 25,
26]. The primers were designed by the following method.
First, the primer sequences were found from a public
resource for PCR primers, PrimerBank website [27]. To
prevent the amplification of genomic DNA, two PCR
primers (forward and reverse) were designed to span exon-
exon junctions for the gene transcript of interest. The length
of the primers was approximately 20−25 bases and the
melting temperature (Tm) was approximately 60−62°C.
5µl cDNAs were preamplified using 10 µl of 2X Taqman
preamp Master Mix (Applied BioSystems Cat# 4391128), 2
µl of 500 nM pooled primer mixture and 3 µl of Nuclease-
Free water (Ambion AM9937). The preamplification
program was 95 °C for 10 min, 95 °C for 15 s, 60 °C for 4
min for various cycles. Subsequently, the preamplifiedcD‐
NAs were incubated with 1.6 µl of Exonuclease I (New
England Biolabs Cat# M0293), 0.8 µl of Exonuclease I
reaction buffer, 5.6µl of water in 37°C for 30 min and
inactivated in 80°C for 15 min. The exonuclease treated
samples were further diluted 5-fold using TE (TEKnova PN
T0224) and the gene expressions were analysed with 48.48
Dynamic Arrays on a BioMark System (Fluidigm).
In order to assess the sensitivity of our analysis method, the
Ct values of GAPDH for different numbers of SKBR3 and
MCF7 cells were compared. For this measurement, the cells
were directly prepared on PEN-coated glass slides and
stained with FITC. The cells were then observed under a
fluorescent microscope and known numbers [2-20] of cells
were picked up by a laser microdissection. After cDNA was
produced from the extracted mRNA, the samples were
preamplified by 20 or 23 cycles and analysed by qPCR
(StepOne Plus, Applied Biosystems). The result is shown in
Figure 4. The curves were found by fitting the theoretically
expected formula of Ct = A – log2N to the measured Ct
values. It was shown that the Ct values for GAPDH directly
related to the number of cells that were tested.
Figure 4. The Ct values for GAPDH with different numbers of cancer cells.
The number of cancer cells tested ranged from 2 to 20.
Along with the single cell experiment, the appropriateness
of the choice of primers was tested using a qPCR analysis
of a few thousand cells for each of the cell lines including
MCF7, SKBR3 and MDAMB231. The cells were directly
prepared from culture dishes. The Biomark HD system was
used in this test. Figure 5 shows the relative expression
levels. Expressions of UBB were used as references. The
values were scaled by log2X (larger, higher expression) and
normalized by the whole data set for each primer (i.e., the
average expression level of three cell lines for each primer
was set to zero). As listed below, the expected characteris‐
tics were observed.
• The MCF7 cells (luminal) showed the highest ER and PR
expressions
• The SKBR3 (HER2+) cells showed the highest HER2 and
GRB7 expressions
• The MDAMB231 cells showed the lowest expressions of
EPCAM and KRT
Figure 5. The relative expression values of the reference cancer cells (a few
thousand cells) for the primers that were used in this study. The values were
scaled by log2X and normalized by the whole data set for each primer. We
used breast cancer cell lines of MCF7, SKBR3 and MDAMB231 to model ER/
PR+, HER2+, and triple negative (TN) breast cancer cells, respectively.
2.4 Single Cell PCR Analysis
A single cell PCR analysis of cancer cells separated from
blood was performed. After the cancer cells were captured,
stained and identified on the substrate, from one to five, the
cancer cells were picked up by laser cutting for each PCR
tube. For both MCF7 and SKBR3, 11 samples were each
prepared with the cancer cells spiked into and retrieved
from blood, and three were prepared from the control
slides (the slides where the cells were directly dropcast).
Due to the low expression of EPCAM and cytokeratin, it
was much more difficult to separate the MDAMB231 cancer
cell from blood than the other two cell lines. For
MDAMB231, one sample was prepared from a spiked
sample and the other seven samples were made from
control slides. The samples were then processed with the
Biomark HD system. Figure 6 shows the result. Each
combination of sample and primer was duplicated and the
average was used. A heat map showing all of the measure‐
ments obtained from the raw data is shown in Figure 8 in
the Methods section. On average, the measured expression
levels coincided with the results that were obtained from
the reference cells (a few thousand cells) in Figure 5.
Although the trend was less significant for the single cell
analysis, most of the primers showed a tendency that was
expected from the characteristics of ER/PR+, HER2 and TN
cells. However, when we looked at the values from each
sample, there were cases where the results contradicted
what we had expected. It is worth noting that gene expres‐
sions that are measured from a cell population do not
necessarily represent the expression levels in single cells
[28]. In this study, some primers showed noticeable
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deviations amongst the samples, while other primers had
fewer deviations. Here are two interesting examples:
• The MCF7 cells (typically considered ER positive)
obviously showed intense expression levels of ER on
average. However, some single cells had lower expres‐
sion levels than the SKBR3 cells (typically considered ER
negative).
• Positive expression levels of GRB7 were only found with
the SKBR3 cells, and all of the other cells showed
negative values (see also Figure 8 in the Methods
section).
These indicate that some of the markers that are usually
used to identify types of cancers may not work properly for
a single cell analysis. Cell heterogeneity is a critical factor
that is relevant to a single cell analysis. The primers that
show smaller deviations should be used to supplement an
analysis for single cell cancer profiling.
Figure 6. The result of the single cell analysis. The relative expression values
for the single cell samples were plotted. The values were scaled by log2X and
normalized by the whole data set for each primer. For MCF7 and SKBR3,
the single cells that were spiked into and captured from blood samples were
used. For MDAMB231, the control cells (single cells directly prepared on a
glass substrate) were used.
3. Conclusion
We have demonstrated a technique for a single cell PCR
analysis of CTCs that is based on microfluidic immuno‐
magnetic separation. Small numbers of cancer cells (from
one to five) were successfully separated from blood
samples and tested in a commercially available microflui‐
dic PCR system. This method used standard glass slides
and is compatible with most of the existing microscopic
observation techniques. The results showed a good match
with the result that was obtained from a few thousand cells.
It is also important to note that the single cell analysis
showed larger deviations in expression levels, and some
markers (e.g., ER, HER2) that are commonly used for cancer
cell identification may not represent the characteristics of
individual cells. Other primers (e.g., GRB7) showed smaller
deviations and may be more suitable for single cell profil‐
ing. The results have shown the feasibility of using CTCs
as the source of a detailed genomic analysis of tumours or
future “liquid biopsy”, which is based on a blood analysis.
4. Methods
4.1 Single Cell RNA Extraction
Figure 7 shows the PCR tube and a cut film that has three
cancer cells. After a cut film was placed on the cap of a PCR
tube, the steps of an RNA extraction were performed within
the cap to reduce the volume of the reagents that were used.
The tube was kept upside down during the extraction. First,
0.2 µL of RNA GEM was added onto the cap. The tube was
incubated at 75ºC for 5 min, and 0.28 µL of TE buffer was
added.
Figure 7. Single cell preparation. (a) A laser cut PEN film was placed onto
the adhesive part of the PCR tube. (b) The number of cells that were picked
up for each tube ranged from 1 to 5. (c) The film thickness was approximately
3µm. It was viewed with a viewing angle of about 45 degrees.
4.2 Single Cell qPCR Analysis
Figure 8 shows a heat map of the measurements with the
FluidigmBiomark System. The expression levels of UBB
were used as the reference. For each primer, the values were
normalized by the average of the whole set of samples. The
values lower than -3 or higher than 3 are treated as -3 or 3,
respectively. The blank panels mean “undetectable.”
Figure 8. Heat map obtained from 40 samples and nine primers. Each
mixture of a sample and a primer was duplicated, and the average was used
in the map. Each sample contained 1-5 single cells. The control cells were
cells that were directly prepared on a PEN-coated glass slide. The spiked
cells were spiked into a blood sample and captured on a PEN-coated glass
slide by the immunomagnetic separation. For GRB7, the intense expressions
(shown in red) were only found with the SKBR3 cells.
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